Alexander Lyubimov

Oversees one of only 5 labs in the USA granted an NCI contract to study safety and toxicity of new anticancer drugs. He has conducted numerous preclinical efficacy and safety programs on potential therapeutic agents and devices, the results of which were used for over 30 successful drug submissions and approvals by the FDA. He has recently designed, directed and overseen the entire IND packages of 3 drugs successfully approved by the FDA for clinical trials.